Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products
复制标题
DOI:
10.1158/0008-5472.can-04-4439
复制
发表时间:
2005-07-15
期刊:
影响因子:
11.2
通讯作者:
Menter, DG
中科院分区:
文献类型:
--
作者:
Kim, J;Yang, PY;Menter, DG
Stromal-epithelial interactions and the bioactive molecules produced by these interactions maintain tissue homeostasis and influence carcinogenesis. Bioactive prostaglandins produced by prostaglandin synthases and secreted by the prostate into seminal plasma are thought to support reproduction, but their endogenous effects on cancer formation remain unresolved. No studies to date have examined prostaglandin enzyme production or prostaglandin metabolism in normal prostate stromal cells. Our results show that lipocalin-type prostaglandin D synthase (L-PGDS) and prostaglandin D-2 (PGD(2)) metabolites produced by normal prostate stromal cells inhibited tumor cell growth through a peroxisome proliferator-activated receptor gamma (PPAR gamma)-dependent mechanism. Enzymatic products of stromal cell L-PGDS included high levels of PGD2 and 15-deoxy-Delta(12,14) -PGD(2) but low levels of 15-deoxy-Delta(12,14) -prostaglandin J(2). These PGD(2) metabolites activated the PPAR gamma ligand-binding domain and the peroxisome proliferator response element reporter systems. Thus, growth suppression of PPAR gamma-expressing tumor cells by PGD(2) metabolites in the prostate microenvironment is likely to be an endogenous mechanism involved in tumor suppression that potentially contributes to the indolence and long latency period of this disease.